^
3ms
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma (clinicaltrials.gov)
P1, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2024 --> Nov 2024 | Trial primary completion date: Jun 2024 --> Nov 2024
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
MB-103
9ms
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases (clinicaltrials.gov)
P1, N=39, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Feb 2025 | Trial primary completion date: Dec 2023 --> Feb 2025
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 amplification
|
MB-103
11ms
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma (clinicaltrials.gov)
P1, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
MB-103
1year
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases (clinicaltrials.gov)
P1, N=39, Recruiting, City of Hope Medical Center | Trial completion date: Aug 2023 --> Dec 2023 | Trial primary completion date: Aug 2023 --> Dec 2023
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 amplification • HER-2 expression
|
MB-103
3years
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases (clinicaltrials.gov)
P1, N=39, Recruiting, City of Hope Medical Center | Trial completion date: Aug 2021 --> Aug 2023 | Trial primary completion date: Aug 2021 --> Aug 2023
Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 amplification • HER-2 expression
|
MB-103
over3years
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma (clinicaltrials.gov)
P1, N=42, Recruiting, City of Hope Medical Center | Trial completion date: Jun 2021 --> Dec 2023 | Trial primary completion date: Jun 2021 --> Dec 2023
Clinical • Trial completion date • Trial primary completion date • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
MB-103